Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 84
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Clin Dermatol ; 2024 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-38925446

RESUMO

Artificial intelligence (AI) is a rapidly developing field with the potential to transform various aspects of health care and public health, including medical training. The utility of AI is still being studied to understand better how to integrate its innumerable applications into modern medicine and how it is taught. Medical school dermatology education in particular stands to benefit from AI, especially when considering medical schools that lack dermatology curriculums. In this review, we evaluate the integration of AI technology in the field of dermatology and how it can inform how dermatology is taught in medical schools across the United States.

2.
3.
Clin Dermatol ; 41(6): 661-663, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37739189
4.
JAMA Dermatol ; 159(10): 1131-1132, 2023 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-37610788

RESUMO

A woman in her 60s with long-standing thickening and induration of the legs presented with 1 week of left leg pain. Physical examination results revealed multiple firm skin-colored papules and nodules coalescing to form a large plaque on the anterior aspect of the left lower leg, whereas the right lower leg had diffuse induration and hyperpigmentation. What is your diagnosis?


Assuntos
Anormalidades da Pele , Neoplasias Cutâneas , Humanos , Perna (Membro) , Neoplasias Cutâneas/diagnóstico
8.
Arch Dermatol Res ; 315(6): 1755-1762, 2023 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-36463367

RESUMO

Cosmetic dermatology is a key subspecialty of academic dermatology. As such, academic centers are expected to demonstrate excellence in the teaching of cosmetic dermatology skills to trainees, the clinical delivery of cosmetic dermatology services to patients, and the performance of clinical research that advances knowledge and uncovers new therapies in cosmetic dermatology. The Association of Academic Cosmetic Dermatology (AACD), a newly formed medical professional society, includes as its principal aims the support of all of these areas. AACD is comprised of group of board-certified dermatologists who teach cosmetic and laser dermatology at US dermatology residency programs. An expert panel constituted by the AACD recently convened a workshop to review gaps pertaining to academic cosmetic dermatology. This panel considered needs and potential corrective initiatives in three domains: resident education, patient experience, and clinical research. The work of the panel was used to develop a roadmap, which was adopted by consensus, and which will serve to guide the AACD moving forward.


Assuntos
Dermatologia , Internato e Residência , Humanos , Dermatologia/educação , Assistência ao Paciente , Sociedades Médicas
9.
Arch Dermatol Res ; 315(5): 1449-1452, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-36456760

RESUMO

Cosmetic and laser procedures are increasingly popular among patients and are skills in which dermatologists are regarded as well trained. Most dermatology residents intend to incorporate cosmetic procedures into their practice and prefer to learn such procedures during residency through direct patient care. However, there are notable challenges in optimizing how residents are trained in cosmetic and laser dermatology. To address these barriers and elevate the practice of cosmetic dermatology in academic medicine, the Association of Academic Cosmetic Dermatology (AACD) was founded in 2021 as the lead professional society for dermatologists who direct the education of resident trainees in cosmetic and laser dermatology. The AACD, a group of board-certified dermatologists who teach cosmetic and laser dermatology to residents, aims to improve cosmetic dermatology education through collaboration, research, and advocacy.


Assuntos
Dermatologia , Internato e Residência , Humanos , Dermatologia/educação , Currículo , Inquéritos e Questionários
13.
Clin Dermatol ; 40(6): 619-621, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35961482
15.
Clin Dermatol ; 39(6): 1032-1038, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34920821

RESUMO

Underrepresented in medicine (URiM) are individuals from racial and ethnic populations that are underrepresented in the medical field relative to their numbers in the general population. International medical graduates (IMGs) compose a significant percentage of URiM individuals, with a meaningful role in the current US health care workforce. Currently, there is limited data on IMGs in dermatology. In this paper, we wish to showcase reliable data about the IMG pool and highlight their value in diversifying dermatology in order to better serve our patients and provide culturally competent care.


Assuntos
Dermatologia , Humanos
16.
Clin Dermatol ; 39(6): 931-933, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34920832
17.
J Immunother Cancer ; 9(10)2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34599027

RESUMO

BACKGROUND: Limited data exist on safe discontinuation of antiprogrammed cell death protein 1 (PD-1) therapy in responding patients with advanced melanoma. The use of 18fluorodeoxyglucose (18FDG)-PET/CT scan and tumor biopsy for assessment of active disease may be an effective predictive biomarker to guide such treatment decisions. METHODS: A retrospective study of 122 patients with advanced melanoma treated with anti-PD-1 monotherapy or anti-PD-1/anticytotoxic T-lymphocyte-associated protein 4 combination therapy at Georgetown Lombardi Comprehensive Cancer Center was conducted. Uveal melanoma patients and those receiving concurrent experimental therapy were excluded. Baseline characteristics, treatment outcomes, and survival were analyzed. Patients who decided to come off treatment typically after 12 months using CT scan radiographic complete response (CR), 18FDG-PET/CT scan complete metabolic response (CMR) or tumor biopsy of a non-CR/CMR tumor site negative for active disease (possible pathological CR) were identified and compared with patients who discontinued treatment due to toxicity while their disease was in control. Event-free survival (EFS) was assessed from the last dose of anti-PD-1 therapy to progression requiring subsequent treatment (surgery, radiation, and/or systemic therapy) or referral to hospice/death due to melanoma. RESULTS: 24 (20%) patients discontinued treatment by choice with no active disease and 28 (23%) patients discontinued treatment due to toxicity with disease control after 12-month and 4-month median treatment durations, respectively. Similar baseline characteristics were observed between cohorts except higher prior receipt of ipilimumab (29% vs 7%; p=0.036) and fewer BRAF mutant positive disease (17% vs 41%; p=0.064) in patients off treatment by choice. Three-year EFS rates were 95% and 71%, respectively. No significant associations between EFS and sex, disease stage, lactate dehydrogenase elevation, BRAF status, prior systemic therapy, ECOG performance status, presence of brain metastases, or combination versus monotherapy were observed. Tumor biopsies led to alternative management in 3/10 patients due to active metastatic melanoma or second malignancy. CONCLUSIONS: Anti-PD-1 therapy discontinuation after 12 months when no active disease is observed on CT scan, PET/CT scan or tumor biopsy may have low rates of disease relapse in patients with advanced melanoma. Biopsy of residual disease may frequently lead to a change in management. These findings are undergoing validation in the EA6192 trial.


Assuntos
Biópsia/métodos , Imunoterapia/métodos , Melanoma/diagnóstico por imagem , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada/métodos , Receptor de Morte Celular Programada 1/antagonistas & inibidores , Idoso , Feminino , Humanos , Masculino , Melanoma/tratamento farmacológico , Pessoa de Meia-Idade , Estudos Retrospectivos , Resultado do Tratamento
18.
Clin Dermatol ; 39(3): 380-383, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34517996

RESUMO

More than 40 million people have been infected with the severe acute respiratory syndrome coronavirus 2 since the first infection was reported in December 2019 from Wuhan, China. Multiple reports of cutaneous manifestations of the virus have been described, including a pernio-like eruption, recently termed "COVID toes." We have reviewed the published case series on "COVID toes" in addition to studies identifying possible pathogenic mechanisms behind the eruption.


Assuntos
COVID-19 , Pérnio , Exantema , Pérnio/diagnóstico , Pérnio/epidemiologia , Humanos , SARS-CoV-2 , Dedos do Pé
19.
Clin Dermatol ; 39(3): 424-429, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34518000

RESUMO

The Coronavirus Disease 2019 (COVID-19) pandemic is a recent, ongoing global infection that has affected more than 200 countries worldwide, with the United States having the highest per capita infection rate. Professional organizations, accrediting bodies, licensing boards, and government agencies have been important partners to academic institutions and the health care system during this pandemic response. We review the American perspective of the impact of COVID-19 on dermatology.


Assuntos
COVID-19 , Humanos , Pandemias , SARS-CoV-2 , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...